Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemi

来源 :The 35th World Congress of the International Society of Hema | 被引量 : 0次 | 上传用户:lusx
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background A recent GWAS analysis of B-cell chronic lymphocytic leukemia (CLL) identified 12 risk loci,some of which harbor apoptosis-related tumor suppressor genes.Herein we postulate that miR-3151,localized to one GWAS-identified risk locus (8q22.3),is a tumor suppressor gene hypermethylated in CLL.
其他文献
Background Transplantation of cells,tissues,and organs has been recognized by the World Health Organization (WHO) as an important medical task for its member states.
会议
HLA-mismatched/haploidentical transplantation for high-risk hematologic malignancies is associated with the increased risk of severe aGVHD,and poor overall survival (OS).We conducted a haploidentical
会议
Objective As the engraftment failure and opportunistic infections are still the main obstacles of unrelated cord blood transplantation (UCBT),the selection of conditioning regimen become a key factor
会议
Background The number of uCBT is increasing to the level of 1200 cases per year,which is comparable to those of uBMT and rPBSCT in Japan.However there is few data on the comparative outcomes of adult
会议
Objective To investigate the safety and effectiveness of laparoscopic splenectomy (LS) for immune thrombocytopenia patients with platelet count lower than 10×109/L and the long-term prognosis of LS fo
会议
Backgroud Both peripheral blood (PB) and bone marrow (BM) can be used for molecular monitoring by quantitative real-time RT-PCR (Q-PCR) for chronic myeloid leukemia(CML).Aim To determine whether molec
会议
Objective Impaired megakaryocyte maturation and insufficient platelet production participate in the pathogenesis of primary immune thrombocytopenia (ITP).The demethylating agent,decitabine (DAC) has b
会议
Background CLL is one of the most common forms of leukemia among adults.Despite advances in the treatment of CLL,including chemotherapy,chemoimmunotherapy (CIT),and stem cell transplant (SCT),the dise
会议
Background Although chemoimmunotherapy regimens remain the standard in the initial treatment of younger,fit patients with CLL/SLL,relapses are typical.The treatment of older patients,patients with rel
会议
Background Chronic B lymphoproliferative diseases (BLPD),which are mainly compo sed of chronic lymphocytic leukemia (CLL),hairy cell leukemia (HCL),follicular lymphom a (FL),marginal zone lymphoma (MZ
会议